Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda
- PMID: 29654751
- PMCID: PMC6197833
- DOI: 10.1016/j.contraception.2018.03.032
Continuation of injectable contraception when self-injected vs. administered by a facility-based health worker: a nonrandomized, prospective cohort study in Uganda
Abstract
Objective: The purpose of this study was to compare 12-month continuation rates for subcutaneous depot medroxyprogesterone acetate (DMPA-SC) administered via self-injection and DMPA-IM administered by a health worker in Uganda.
Study design: Women seeking injectable contraception at participating health facilities were offered the choice of self-injecting DMPA-SC or receiving an injection of DMPA-IM from a health worker. Those opting for self-injection were trained one-on-one. They self-injected under supervision and took home three units, a client instruction guide and a reinjection calendar. Those opting for DMPA-IM received an injection and an appointment card for the next facility visit in 3 months. We interviewed participants at baseline (first injection) and after 3 (second injection), 6 (third injection) and 9 (fourth injection) months, or upon discontinuation. We used Kaplan-Meier methods to estimate continuation probabilities, with a log-rank test to compare differences between groups. A multivariate Cox regression identified factors correlated with discontinuation.
Results: The 12-month continuation rate for the 561 women self-injecting DMPA-SC was .81 [95% confidence interval (CI) .78-.84], and for 600 women receiving DMPA-IM from a health worker, it was .65 (95% CI .61-.69), a significant difference at the .05 level. There were no differences in pregnancy rates or side effects. The multivariate analysis revealed that, controlling for covariates, self-injecting reduced the hazard for discontinuing by 46%. A significant interaction between injection group and age suggests that self-injection may help younger women continue injectable use.
Conclusions: The significant difference in 12-month continuation between women self-injecting DMPA-SC and women receiving DMPA-IM from a health worker - which remains significant in a multivariate analysis - suggests that self-injection may improve injectable contraceptive continuation.
Implications: While injectable contraceptives are popular throughout much of sub-Saharan Africa, they have high rates of discontinuation. This study is the second from an African country to demonstrate that self-injection may improve injectable continuation rates and may do so without increasing the risk of pregnancy or adverse events.
Keywords: DMPA-SC; Discontinuation; Sayana® Press; Self-administration; Self-injection.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.Contraception. 2019 Feb;99(2):137-141. doi: 10.1016/j.contraception.2018.11.001. Epub 2018 Nov 12. Contraception. 2019. PMID: 30439358 Free PMC article.
-
Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda.Contraception. 2018 Nov;98(5):423-429. doi: 10.1016/j.contraception.2018.08.007. Epub 2018 Aug 17. Contraception. 2018. PMID: 30125558 Free PMC article.
-
Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.Lancet Glob Health. 2018 May;6(5):e568-e578. doi: 10.1016/S2214-109X(18)30061-5. Epub 2018 Mar 8. Lancet Glob Health. 2018. PMID: 29526707 Clinical Trial.
-
Injectable contraception: emerging evidence on subcutaneous self-administration.Curr Opin Obstet Gynecol. 2019 Dec;31(6):464-470. doi: 10.1097/GCO.0000000000000574. Curr Opin Obstet Gynecol. 2019. PMID: 31567445 Review.
-
Depo Provera. Position paper on clinical use, effectiveness and side effects.Br J Fam Plann. 1999 Jul;25(2):69-76. Br J Fam Plann. 1999. PMID: 10454658 Review.
Cited by
-
Adolescent and Youth Experiences With Contraceptive Self-Injection in Uganda: Results From the Uganda Self-Injection Best Practices Project.J Adolesc Health. 2023 Jan;72(1):80-87. doi: 10.1016/j.jadohealth.2022.08.010. Epub 2022 Oct 13. J Adolesc Health. 2023. PMID: 36243559 Free PMC article.
-
Ugandan providers' views on the acceptability of contraceptive self-injection for adolescents: a qualitative study.Reprod Health. 2018 Oct 3;15(1):165. doi: 10.1186/s12978-018-0611-7. Reprod Health. 2018. PMID: 30285779 Free PMC article.
-
Self-administration of injectable contraception: a systematic review and meta-analysis.BMJ Glob Health. 2019 Apr 2;4(2):e001350. doi: 10.1136/bmjgh-2018-001350. eCollection 2019. BMJ Glob Health. 2019. PMID: 31179026 Free PMC article.
-
Behavioral Drivers Influencing Women's Decision to Use Self-Injectable Contraception Provided by Community Health Surveillance Assistants in Rural Malawi.Womens Health Rep (New Rochelle). 2025 May 19;6(1):576-585. doi: 10.1089/whr.2025.0022. eCollection 2025. Womens Health Rep (New Rochelle). 2025. PMID: 40538667 Free PMC article.
-
Continuation of self-injected versus provider-administered contraception in Senegal: a nonrandomized, prospective cohort study.Contraception. 2019 Feb;99(2):137-141. doi: 10.1016/j.contraception.2018.11.001. Epub 2018 Nov 12. Contraception. 2019. PMID: 30439358 Free PMC article.
References
-
- Ross J.A., Agwanda A.T. Increased use of injectable contraception in sub-Saharan Africa. Afr J Reprod Health. 2012;16(4):68–80. - PubMed
-
- Castle S., Askew I. Population Council; 2015. Contraceptive discontinuation: reasons, challenges and solutions.
-
- Jain A.K., Winfrey W. Contribution of contraceptive discontinuation to unintended births in 36 developing countries. Stud Fam Plann. 2017;48(3):269–278. - PubMed
-
- Burke H., Mueller M.P., Perry B., Packer C., Bufumbo L., Mbengue D. Observational study of the acceptability of Sayana® Press among intramuscular DMPA users in Uganda and Senegal. Contraception. 2014;89:361–367. - PubMed
-
- Burke H., Mueller M.P., Perry B., Packer C., Bufumbo L., Mbengue D. Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal. Contraception. 2014;89:368–373. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources